Management and Follow-up of Massive Fetomaternal Hemorrhage Requiring High-Dose Rh Immune Globulin: A Case Report

Am J Clin Pathol. 2023 Jul 5;160(1):78-80. doi: 10.1093/ajcp/aqad011.

Abstract

Objectives: Massive fetomaternal hemorrhage (FMH) is rare and reported to be the cause in approximately 3% of all fetal deaths. Maternal management of massive FMH includes prevention of Rh(D) alloimmunization in Rh(D)-negative mothers by administration of Rh(D) immune globulin (RhIG).

Methods: We describe a case of a 30-year-old O-negative, primigravida woman who presented at 38 weeks of gestation with decreased fetal movements. She underwent an emergency cesarean section and delivered an O-positive baby girl who died shortly after birth.

Results: The patient's FMH screen was positive, with a Kleihauer-Betke test demonstrating 10.7% fetal blood in maternal circulation. The calculated dose of 6,300 µg RhIG was given prior to discharge over 2 days using an intravenous (IV) preparation. Antibody screening a week after discharge showed anti-D and anti-C. The anti-C was attributed to acquired passive immunity from the large dose of RhIG. Anti-C reactivity waned and was negative at 6 months, but the anti-D pattern persisted at 9 months postdelivery. Negative antibody screens were noted at 12 and 14 months.

Conclusions: This case highlights the immunohematology challenges of IV RhIG as well as the success in preventing alloimmunization with IV RhIG given the patient's complete resolution of anti-C and no anti-D formation, with a subsequent healthy pregnancy.

Keywords: Fetomaternal hemorrhage; Immunology; Rh(D); Transfusion medicine.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cesarean Section
  • Female
  • Fetomaternal Transfusion* / diagnosis
  • Fetomaternal Transfusion* / drug therapy
  • Follow-Up Studies
  • Hemorrhage / drug therapy
  • Humans
  • Pregnancy
  • Rho(D) Immune Globulin / therapeutic use

Substances

  • Rho(D) Immune Globulin